Subcommittee on Antimicrobial Susceptibility Testing – Disclosure Summary

Personal, Professional, and Financial Interests

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities (from past 3 years).

Jean B. Patel, PhD, D(ABMM) – Chairholder
Centers for Disease Control and Prevention

Financial Interests or Benefits: None

Melvin P. Weinstein, MD – Vice Chairholder
Rutgers Robert Wood Johnson Medical School

Financial Interests or Benefits: Research support in 2013-2015 from Beckman Coulter (Siemens), BD Diagnostics, and JMI Laboratories.
Research/speaker honorarium; T2 Biosystems
Consulted for Accelerate Diagnostics and Rempex Pharmaceuticals.

Richard B. Thomson, Jr., PhD- Chairholder, Microbiology Expert Panel
Evanston Hospital, NorthShore University HealthSystem

Financial Interests or Benefits: Received honoraria, consulting fees or research funding in the past three years from International Health Management Associates, BD Kiestra, Nanosphere, and 5 not-for-profit universities and microbiology societies.

Mary Jane Ferraro, PhD, MPH, Vice Chairholder, Microbiology Expert Panel
Massachusetts General Hospital

Financial Interests or Benefits: Research grants to institution from bioMerieux and BD.

Members:

George M. Eliopoulos, MD
Beth Israel Deaconess Medical Center

Financial Interests or Benefits:
Advisory Boards – Bayer, Durata, Nabriva, Paratek, Rempex, and Theravance
Consultation - Shionogi

Stephen G. Jenkins, PhD, D(ABMM),F(AAM)
New York Presbterian Hospital

Financial Interests or Benefits:
Advisory boards for Bayer, Cempra, Cormedix, Insmed, and Merck.

James S. Lewis, II, PharmD, FIDSA
Oregon Health & Science University

Financial Interests or Benefits:
Consultant for – Accelerate Diagnostics, Achaogen, Allergan, Astellas, Merck, Medicines Company, Paratek, and Theravance
Speakers Bureau – Astellas, Forest, Merck
Brandi Limbago, PhD  
Centers for Disease Control and Prevention

Financial Interests or Benefits: None

Amy Mathers, MD  
University of Virginia Medical Center

Financial Interests or Benefits:  
Research: Rempex Pharmaceuticals  
Consultant for Rempex Pharmaceuticals, Accelerate Diagnostics

Tony Mazzulli, MD, FRCP(C), FACP  
Mount Sinai Hospital

Financial Interests or Benefits:  
President: Canadian Association of HIV Clinical Laboratory Specialists  
Speaker Honorarium: Abbott, Merck, Roche  
Advisory Board: bioMerieux, Qvella Corporation, Pfizer, Roche  
Member, Executive Committee, CANCAST

Robin M. Patel, MD  
Mayo Clinic

Financial Interests or Benefits: Employee of Mayo Clinic  
Research funding: BioFire, Check-Points, Curetis, 3M, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, The Medicines Company, NIH  
Consultant: Curetis, Roche, Diaxonhit, Qvella  
Stipends: Journal of Clinical Microbiology, Clinical Infectious Diseases, Manual of Clinical Microbiology  
Co-Chair, ASM Microbe Program Planning Committee  
Patents: B. pertussis and parapertussis PCR, anti-biofilm substance, device/method for sonication  
Honoraria: USMLE, Up-to-Date, Infectious Diseases Board Review Course, NIH

Sandra S. Richter, MD, D(ABMM)  
Cleveland Clinic

Financial Interests or Benefits:  
Research grants – BD Diagnostics, OpGen, bioMerieux, Nanosphere, Cerexa, Pocared, Biofire Diagnostics, Achaogen Pharmaceuticals, Roche  
Speaker honorarium – bioMerieux  
Editor stipen – Journal of Clinical Microbiology, Manual of Clinical Microbiology

Michael J. Satlin, MD, MS  
Weill Cornell Medical College/ NewYork-Presbyterian Hospital

Financial Interests or Benefits: none  
Research grants/contract: Achaogen, Allergan

John D. Turnidge, MD  
Australian Commission for Safety and Quality in Health Care

Financial Interests or Benefits:  
Advisory boards for Novartis Australia, Pfizer Australia and AstraZeneca Australia  
Visiting speaker for bioMeriuxex
5/17/2016
Barbara L. Zimmer, PhD
Beckman Coulter, Inc.

Financial Interests or Benefits: Employee of Beckman Coulter, Inc. which purchased the Microbiology Business Unit (MicroScan) from Siemens Healthcare Diagnostics 2/1/15

Advisors:

Jeff Alder, PhD
Bayer HealthCare Pharmaceuticals

Financial Interests or Benefits: Employee and stockholder for Bayer HealthCare Pharmaceuticals

Other: NIH/NIAID grant and contract reviewer.

Patricia A. Bradford, PhD
AstraZeneca

Financial Interests or Benefits: Employee of AstraZeneca Pharmaceuticals

William B. Brasso, BS
BD Diagnostic Systems

Financial Interests or Benefits: Employee of BD Diagnostic Systems

Dr. Rafael Canton
ESCMID and EUCAST

Financial Interests or Benefits: Ad-hoc member of the ESCMID (the European Society of Clinical Microbiology and Infectious Diseases) Executive Committee. Chairman of EUCAST (European Committee of Antimicrobial Susceptibility Testing).

Graeme Forrest, MBBS
Portland VA Healthcare System

Financial Interests or Benefits: None

Marcelo Galas
National Institute of Infections Diseases, Ministry of Health

Financial Interests or Benefits: None

Howard Gold, MD
Beth Israel Deaconess Medical Center

Financial Interests or Benefits: None

Janet A. Hindler, MCLS, MT(ASCP)
UCLA Health System
APHL

Financial Interests or Benefits:

Speaker's Honoraria: bioMerieux, Inc.; Association of Public Health Labs
Consultant: Accelerate Diagnostics, Inc.
Romney M Humphries, PhD D(ABMM)
UCLA David Geffen School of Medicine

Financial Interests or Benefits:
Research grants to institution- bioMerieux, Beckman Coulter, GenMark, Curetis, BD, Accelarate Diagnostics, Qiagen,
Speaker Honorarium – Merck, Allergan
Advisory Board – Nanosphere, Roche, Cepheid

Thomas J. Kirn, Jr., MD, PhD
Rutgers Robert Wood Johnson Medical School

Financial Interests or Benefits:
Honorarium – Accelarate Diagnostics, Roche, BD

Linda A. Miller, PhD
GlaxoSmithKline

Financial Interests or Benefits: Employee of GlaxoSmithKline Pharmaceuticals

Melissa B. Miller, PhD, D(ABMM)
University of North Carolina School of Medicine

Financial Interests or Benefits: None

Greg Moeck, PhD
The Medicines Company

Financial Interests or Benefits: Employee of The Medicines Company

Sumati Nambiar, MD, MPH
FDA Center for Drug Evaluation and Research

Financial Interests or Benefits: None

David P. Nicolau PharmD, FCCP, FIDSA
Hartford Hospital

Financial Interests or Benefits:
Consultant, grant recipient and/or on the speaker's bureau for the following entities: Achaogen, Actavis, Bayer, Cepheid, Merck, Pfizer, Macrolide Pharmaceuticals, Melinta, Tetraphase, The Medicines Company, Shionogi.

Helio S. Sader, MD, PhD
JMI Laboratories

Financial Interests or Benefits: JMI Laboratories, Inc. has also received research and educational grants in 2012-2014 from Achaogen, Actelion, Affinium, American Proficiency Institute (API), AmpliPhi Bio, Anacor, Astellas, AstraZeneca, Basilea, BioVersys, Cardesa, Cempra, Cerexa, Cubist, Daiichi, Dipexium, Durata, Fedora, Forest, Furiex, Genentech, GlaxoSmithKline, Janssen, Johnson & Johnson, Medpace, Meiji Seika Pharma, Melinta, Merck, Methylgene, Nabriva, Nanosphere, Novartis, Pfizer, Polyphor, Remmex, Roche, Seachaid, Shionogi, Synthes, The Medicines Co., Theravance, ThermoFisher, Venatorx, Vertex and Waterloo. Some JMI employees are advisors/consultants for Astellas, Cubist, Pfizer, Cempra, Cerexa-Forest, and Theravance. In regards to speakers bureaus and stock options-none to declare.
Financial Interests or Benefits:

Speaker Bureau: Merck & Company,

Advisory Boards: BioFire, Cempra Inc., Cepheid, GenMark, Quidel, ThermoFisher, Merck

Audrey N. Schuetz, MD, MPH, D(ABMM)
Mayo Clinic

Financial Interests or Benefits: None

Susan E. Sharp, Ph.D., DABMM, FAAM
ASM

Financial Interests or Benefits: None

Ribhi M. Shawar, Ph.D, D(ABMM)
FDA Ctr. For Devices/Rad. Health

Financial Interests or Benefits: None

Pranita Tamma, MD, MHS
John Hopkins University School of Medicine

Financial Interests or Benefits:

Research grant funded jointly by Pfizer and The Joint Commission entitled “What is the Optimal Antimicrobial Stewardship Strategy: Pre-Prescription Authorization or Post-Prescription Review and Feedback?”

Investigator-initiated grant funded by Merck entitled “The effectiveness of piperacillin-tazobactam versus ertapenem for the treatment of intra-abdominal infections involving Enterococcus faecalis.”

Kazuhiro Tateda, MD, PhD
Toho University School of Medicine

Financial Interests or Benefits: None

Maria M. Traczewski, BS, MT(ASCP)
The Clinical Microbiology Institute

Financial Interests or Benefits:

CMI has received research grants/contracts past and present from the following companies: AstraZeneca, Cubist, ContraFect, GlaxoSmithKline, Pfizer, Pfizer Animal Health, Merck, Astellas, Theravance, Novartis, Paratek, Merck Animal Health, Elanco, Cardeas, bioMerieux, Gilead, Intervet, Vertex, Cornerstone Therapeutics, Cerexa, Shering-Plough Vet. Division, MAP Pharmaceuticals, APP Pharmaceuticals, Novexel, Protez, Leo, Oscient, Achaogen, Trius, Replidyne, Bausch and Lomb, Blanca, Johnson & Johnson, Wyeth, Sanofi-Aventis, Dechrha Pharmaceuticals, APP Pharmaceuticals, Symbionix Therapeutics, Cepheid Inc., Beckman-Seimens, Advanced Food Technologies, Becton-Dickinson, Stanford University, Dermira Inc. and Basilea Pharmaceutica.